BACKGROUND

Psoriasis is one of the most common dermatoses. The adverse impact of COVID-19 on psoriasis course is now increasingly being reported.

OBJECTIVE

To study clinical and epidemiological features of psoriasis course after COVID-19.

MATERIAL AND METHODS

We reviewed outpatient records and case histories of 159 psoriasis patients (84 males and 75 females) who recovered from COVID-19.

RESULTS

The mean age of the patients was 49.9±1.9 years. The majority (55.3%) of patients were aged 50 to 60 years or older. The mean duration of illness was 4.74±0.69 years. The most common comorbidities were diabetes mellitus and obesity. Psoriasis vulgaris was diagnosed in 56% of patients, and different types of pustular psoriasis accounted for 4.4%. Psoriasis guttata was detected in 9 (5.7%) patients, arthropathic psoriasis in 13 (8.2%), exudative psoriasis in 15 (9.4%), psoriatic erythroderma in 14 (8.8%), and psoriatic onychodystrophy in 26 (16.3%) patients. The disease was mild in 12 (7.5%) patients, moderate in 55 (34.6%), and severe in 92 (57.9%) patients. The dermatological quality of life index was 26.6±3.2 points.

CONCLUSION

Diabetes mellitus and obesity were the most common comorbidities. A significant part of the patients had pustular psoriasis, psoriasis guttata, and psoriatic erythroderma. In the post-COVID period, a moderate to severe course of psoriasis was observed in 78% of cases. A high DLQI value indicated an adverse impact of COVID-19 and psoriasis on patients’ quality of life. The features of the psoriasis course in the post-COVID period should be considered when prescribing therapy and medical rehabilitation measures.